Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NARINDER SAINI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1356420665
CMS profile
1142372
Location
SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$12.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $12.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $12.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NARINDER SAINI

NPI 1356420665 · CMS profile ID 1142372

Allopathic & Osteopathic Physicians / Internal Medicine

SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $12.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $12.8304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686626397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,450.00 1
PY2024 Principal investigator $23,855.10 5
PY2023 Recipient $11,082.59 1
PY2023 Principal investigator $9,599.85 7
PY2022 Recipient $3,897.05 1
PY2022 Principal investigator $1,244,253.27 83
PY2021 Recipient $434,945.60 1
PY2021 Principal investigator $917,788.30 69
PY2020 Recipient $15,112.10 3
PY2020 Principal investigator $408,488.40 195
PY2019 Recipient $586.07 1
PY2019 Principal investigator $552,873.53 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

198 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $2,315.68 12/31/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721315449
Principal investigator 1 Allergan, Inc. $5,905.94 12/31/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721315555
Principal investigator 1 Allergan, Inc. $463.96 12/31/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721317887
Principal investigator 1 Allergan, Inc. $1,130.63 12/31/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721317947
Principal investigator 1 Eli Lilly and Company $11,100.00 12/28/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 728751843
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 12/28/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526073
Principal investigator 1 Vanda Pharmaceuticals Inc. $350.00 12/22/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735129189
Principal investigator 1 Allergan, Inc. $700.00 12/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721313545
Principal investigator 1 Eli Lilly and Company $1,173.18 12/17/2020 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 728738947
Principal investigator 1 Vanda Pharmaceuticals Inc. $550.00 12/16/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735129115
Principal investigator 1 Allergan, Inc. $2,428.20 12/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721312437
Principal investigator 1 Eli Lilly and Company $47,438.00 12/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 728751841
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,134.00 12/09/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735129103
Recipient Celltrion, Inc. $12,500.00 12/04/2020 Covered Recipient Physician CT-P17 3.1 No dispute reported 06/30/2026 750196735
Recipient Celltrion, Inc. $2,500.00 12/04/2020 Covered Recipient Physician CT-P17 3.1 No dispute reported 06/30/2026 752345789
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734912147
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734918659
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734918661
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734918895
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922199
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922359
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922361
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922363
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922941
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924569
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924571
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924745
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924823
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924825
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924829
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924831
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926047
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926061
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926063
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926065
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926471
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926473
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926475
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926477
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927465
Principal investigator 1 GlaxoSmithKline, LLC. $97.24 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927859
Principal investigator 1 GlaxoSmithKline, LLC. $88.40 12/04/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734929507
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734912143
Principal investigator 1 GlaxoSmithKline, LLC. $100.10 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734914735
Principal investigator 1 GlaxoSmithKline, LLC. $28.23 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734914737
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734917021
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734917185
Principal investigator 1 GlaxoSmithKline, LLC. $40.82 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734917759
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734918897
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734919213
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734919215
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734919281
Principal investigator 1 GlaxoSmithKline, LLC. $20.70 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734919501
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734920517
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734920519
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734920521
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922195
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922197
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922201
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922415
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922417
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922441
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922443
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922445
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922447
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922479
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922551
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922553
Principal investigator 1 GlaxoSmithKline, LLC. $892.84 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922557
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922559
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922561
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734922577
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924553
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924575
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924577
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924741
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924819
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924833
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924859
Principal investigator 1 GlaxoSmithKline, LLC. $1,201.20 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734924863
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734925051
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734925053
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926037
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926039
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926041
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926045
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926067
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926467
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926469
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926515
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926519
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734926521
Principal investigator 1 GlaxoSmithKline, LLC. $9.41 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927111
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927425
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927427
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.59 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927429
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927431
Principal investigator 1 GlaxoSmithKline, LLC. $832.81 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927461
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.06 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927499
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927851
Principal investigator 1 GlaxoSmithKline, LLC. $2,170.12 12/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734927853
Principal investigator 1 Allergan, Inc. $169.00 11/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721309807
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,000.00 11/24/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128847
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,960.00 11/12/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128671
Principal investigator 1 GlaxoSmithKline, LLC. $65.00 11/11/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965525083
Recipient Eli Lilly and Company $112.10 11/06/2020 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 753910637
Principal investigator 1 Vanda Pharmaceuticals Inc. $34,564.00 11/05/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128489
Principal investigator 1 Allergan, Inc. $1,121.00 11/03/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721306407
Principal investigator 1 Allergan, Inc. $1,235.00 10/21/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721304625
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 10/14/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526065
Principal investigator 1 GlaxoSmithKline, LLC. $20.70 10/14/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526079
Principal investigator 1 Eli Lilly and Company $5,878.92 10/09/2020 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 728748985
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,106.00 10/07/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128173
Principal investigator 1 Allergan, Inc. $1,000.00 10/01/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721301311
Principal investigator 1 Allergan, Inc. $1,500.00 10/01/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721301315
Principal investigator 1 Allergan, Inc. $327.00 09/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721300793
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721299099
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721299429
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299637
Principal investigator 1 Allergan, Inc. $3,842.75 09/17/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721298405
Principal investigator 1 Allergan, Inc. $1,000.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721297311
Principal investigator 1 Allergan, Inc. $1,500.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721297315
Principal investigator 1 Allergan, Inc. $1,500.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721297769
Principal investigator 1 Allergan, Inc. $1,500.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721297773
Principal investigator 1 Allergan, Inc. $1,000.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721297777
Principal investigator 1 Allergan, Inc. $1,000.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721297811
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,530.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128077
Principal investigator 1 Vanda Pharmaceuticals Inc. $750.00 09/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128087
Principal investigator 1 Allergan, Inc. $327.00 09/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721295829
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.00 09/08/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127923
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,900.00 09/08/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127939
Principal investigator 1 Allergan, Inc. $2,000.00 09/04/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721295643
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,000.00 09/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749679755
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,797.00 09/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749683157
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $75.00 09/01/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749684381
Principal investigator 1 Allergan, Inc. $955.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721293867
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,500.00 08/26/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127813
Principal investigator 1 GlaxoSmithKline, LLC. $1,530.00 08/25/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526063
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $196.50 08/25/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749678507
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,500.00 08/25/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749685535
Principal investigator 1 Allergan, Inc. $420.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721291755
Principal investigator 1 Allergan, Inc. $327.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721292369
Principal investigator 1 Allergan, Inc. $385.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292667
Principal investigator 1 Allergan, Inc. $1,225.50 08/19/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721291537
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,700.00 08/17/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127677
Principal investigator 1 Allergan, Inc. $3,893.10 08/13/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721289915
Principal investigator 1 Allergan, Inc. $1,121.00 08/13/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721290233
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 08/10/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526071
Principal investigator 1 GlaxoSmithKline, LLC. $1,530.00 07/14/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526067
Principal investigator 1 GlaxoSmithKline, LLC. $1,700.00 07/11/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526069
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 07/09/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526077
Principal investigator 1 Vanda Pharmaceuticals Inc. $10,800.00 07/08/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127287
Principal investigator 1 Allergan, Inc. $1,225.50 06/24/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721281785
Principal investigator 1 Allergan, Inc. $4,206.60 06/18/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721280743
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 06/10/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965526075
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/03/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734917461
Principal investigator 1 Allergan, Inc. $1,225.50 06/02/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721278549
Principal investigator 1 Allergan, Inc. $385.00 05/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721277231
Principal investigator 1 Allergan, Inc. $1,276.80 05/21/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721276401
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $5,906.00 05/21/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749684387
Principal investigator 1 Allergan, Inc. $1,121.00 05/20/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721275997
Principal investigator 1 Allergan, Inc. $325.00 05/08/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273931
Principal investigator 1 Allergan, Inc. $3,809.50 05/08/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273933
Principal investigator 1 Allergan, Inc. $385.00 04/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721272141
Principal investigator 1 GlaxoSmithKline, LLC. $9,900.00 04/17/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 734915797
Principal investigator 1 Allergan, Inc. $18,544.00 04/16/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721270715
Principal investigator 1 Allergan, Inc. $6,691.80 04/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721270319
Principal investigator 1 Allergan, Inc. $1,178.00 04/06/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721268927
Principal investigator 1 Allergan, Inc. $2,400.00 04/01/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721268169
Principal investigator 1 Allergan, Inc. $371.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721267537
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.00 03/25/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125849
Principal investigator 1 Allergan, Inc. $1,301.50 03/18/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721265879
Principal investigator 1 Allergan, Inc. $4,742.40 03/17/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721265143
Principal investigator 1 Allergan, Inc. $2,403.50 03/16/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721264455
Principal investigator 1 Allergan, Inc. $1,225.50 03/16/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721264561
Principal investigator 1 Allergan, Inc. $400.00 03/11/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721263207
Principal investigator 1 Allergan, Inc. $250.00 03/11/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721263209
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,200.00 03/11/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125477
Principal investigator 1 Vanda Pharmaceuticals Inc. $350.00 03/11/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125479
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,297.00 03/11/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125481
Principal investigator 1 Allergan, Inc. $2,400.00 03/04/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721261911
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721260379
Principal investigator 1 Allergan, Inc. $700.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721260591
Principal investigator 1 Allergan, Inc. $1,276.80 02/25/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721260875
Principal investigator 1 Genentech, Inc. $6,500.00 02/25/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
TRANSMISSION STUDY HOUSEHOLD No dispute reported 06/30/2026 743191045
Principal investigator 1 Genentech, Inc. $940.00 02/25/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
TRANSMISSION STUDY HOUSEHOLD No dispute reported 06/30/2026 743191063
Principal investigator 1 Allergan, Inc. $1,615.00 02/24/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259205
Principal investigator 1 Allergan, Inc. $3,173.00 02/24/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259207
Principal investigator 1 Allergan, Inc. $3,344.00 02/24/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721259547
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,400.00 02/12/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125097
Principal investigator 1 Allergan, Inc. $3,340.20 02/05/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721255989
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,197.00 02/05/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124831
Principal investigator 1 Allergan, Inc. $327.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721255509
Principal investigator 1 Allergan, Inc. $5,000.00 02/03/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721255067
Principal investigator 1 Allergan, Inc. $115.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721250841
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $6,874.00 01/21/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749684397
Principal investigator 1 Allergan, Inc. $3,306.00 01/15/2020 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721248145
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $3,394.50 01/07/2020 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
MCP-103-205 No dispute reported 06/30/2026 749684393